trump glp 1 executive order Weight-loss drug makers announce pricing agreement with Trump signs order that could

Imagine Drucker submitting a grant proposal today titled "Investigating Gila Monster Venom Proteins for Potential Therapeutic Applications." How would reviewers respond to: Unclear commercial potential No obvious connection to existing treatment paradigms High risk of "failure" (most venom studies don't yield drugs) Difficult to measure short-term impact Traditional funding metrics, publication counts, citation indices, immediate clinical relevance, would likely work against such proposals

HSA/FSA eligible

The efficacy of CQ can be enhanced by GSH depletion and GST inhibition

bioRxiv2024 July 05

Bodycare ingredients The growing interest in beef tallow and turmeric suggests a fascination with natural bodycare ingredients, as well as a preference for straightforward and efficient bodycare choices

Stiewig-Rapp is the incoming director of a new Obesity Clinic the health system is set to open in 2026